Briacell receives recommendation from safety board

Executive Summary

• Briacell Therapeutics received its fifth consecutive positive recommendation from the independent Data Safety Monitoring Board (DSMB) regarding the safety of its pivotal Phase 3 Bria-ABC study.
• The DSMB raised no safety concerns and recommended that the study continue without modifications.
• The trial evaluates Bria-IMT combined with an immune checkpoint inhibitor for metastatic breast cancer and is conducted under FDA fast-track designation.

Key Details

• Study Name & Identifier: Pivotal Phase 3 Bria-ABC study (NCT06072612)
• Treatment Regimen: Bria-IMT plus immune checkpoint inhibitor
• Target Indication: Metastatic breast cancer
• DSMB Review Outcome: Fifth consecutive positive recommendation; no safety concerns identified; study continues as planned.
• Review Schedule: Quarterly meetings in accordance with the study protocol.
• Regulatory Status: FDA fast-track designation granted, reflecting significant unmet medical need in the metastatic breast cancer space.
• Company Profile: Briacell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.

Notable Quotes

• Dr. William V. Williams, President & CEO: "This marks the fifth consecutive DSMB review supporting the continued conduct of Briacell's pivotal phase 3 Bria-ABC study... We are encouraged by the DSMB's ongoing confirmation of the safety profile of the Bria-IMT regimen and remain focused on advancing this program for patients with limited treatment options. We look forward to providing additional clinical updates as the study progresses."